The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pancreatic Endocrine Tumor Drug Market Research Report 2025
Synopsis
The global Pancreatic Endocrine Tumor Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pancreatic Endocrine Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pancreatic Endocrine Tumor Drug.
Report Scope
The Pancreatic Endocrine Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pancreatic Endocrine Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pancreatic Endocrine Tumor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
MediaPharma s.r.l.
Novartis AG
OXiGENE, Inc.
Segment by Type
Buparlisib Hydrochloride
Dovitinib Lactate
Fosbretabulin Tromethamine
Lanreotide Acetate
MPHE-001B
Others
Segment by Application
Clinic
Research Center
Hospital
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pancreatic Endocrine Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pancreatic Endocrine Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Pancreatic Endocrine Tumor Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pancreatic Endocrine Tumor Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pancreatic Endocrine Tumor Drug.
Report Scope
The Pancreatic Endocrine Tumor Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pancreatic Endocrine Tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pancreatic Endocrine Tumor Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
MediaPharma s.r.l.
Novartis AG
OXiGENE, Inc.
Segment by Type
Buparlisib Hydrochloride
Dovitinib Lactate
Fosbretabulin Tromethamine
Lanreotide Acetate
MPHE-001B
Others
Segment by Application
Clinic
Research Center
Hospital
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pancreatic Endocrine Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pancreatic Endocrine Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pancreatic Endocrine Tumor Drug Market Overview
1.1 Product Overview and Scope of Pancreatic Endocrine Tumor Drug
1.2 Pancreatic Endocrine Tumor Drug Segment by Type
1.2.1 Global Pancreatic Endocrine Tumor Drug Market Value Comparison by Type (2024-2030)
1.2.2 Buparlisib Hydrochloride
1.2.3 Dovitinib Lactate
1.2.4 Fosbretabulin Tromethamine
1.2.5 Lanreotide Acetate
1.2.6 MPHE-001B
1.2.7 Others
1.3 Pancreatic Endocrine Tumor Drug Segment by Application
1.3.1 Global Pancreatic Endocrine Tumor Drug Market Value by Application: (2024-2030)
1.3.2 Clinic
1.3.3 Research Center
1.3.4 Hospital
1.4 Global Pancreatic Endocrine Tumor Drug Market Size Estimates and Forecasts
1.4.1 Global Pancreatic Endocrine Tumor Drug Revenue 2019-2030
1.4.2 Global Pancreatic Endocrine Tumor Drug Sales 2019-2030
1.4.3 Global Pancreatic Endocrine Tumor Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pancreatic Endocrine Tumor Drug Market Competition by Manufacturers
2.1 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pancreatic Endocrine Tumor Drug Average Price by Manufacturers (2019-2024)
2.4 Global Pancreatic Endocrine Tumor Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pancreatic Endocrine Tumor Drug, Product Type & Application
2.7 Pancreatic Endocrine Tumor Drug Market Competitive Situation and Trends
2.7.1 Pancreatic Endocrine Tumor Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pancreatic Endocrine Tumor Drug Players Market Share by Revenue
2.7.3 Global Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pancreatic Endocrine Tumor Drug Retrospective Market Scenario by Region
3.1 Global Pancreatic Endocrine Tumor Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pancreatic Endocrine Tumor Drug Global Pancreatic Endocrine Tumor Drug Sales by Region: 2019-2030
3.2.1 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2019-2024
3.2.2 Global Pancreatic Endocrine Tumor Drug Sales by Region: 2025-2030
3.3 Global Pancreatic Endocrine Tumor Drug Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2019-2030
3.3.1 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2019-2024
3.3.2 Global Pancreatic Endocrine Tumor Drug Revenue by Region: 2025-2030
3.4 North America Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
3.4.1 North America Pancreatic Endocrine Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pancreatic Endocrine Tumor Drug Sales by Country (2019-2030)
3.4.3 North America Pancreatic Endocrine Tumor Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
3.5.1 Europe Pancreatic Endocrine Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pancreatic Endocrine Tumor Drug Sales by Country (2019-2030)
3.5.3 Europe Pancreatic Endocrine Tumor Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pancreatic Endocrine Tumor Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Pancreatic Endocrine Tumor Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
3.7.1 Latin America Pancreatic Endocrine Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2019-2030)
3.7.3 Latin America Pancreatic Endocrine Tumor Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2019-2030)
4.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Type (2019-2024)
4.1.2 Global Pancreatic Endocrine Tumor Drug Sales by Type (2025-2030)
4.1.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type (2019-2030)
4.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2019-2030)
4.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2019-2024)
4.2.2 Global Pancreatic Endocrine Tumor Drug Revenue by Type (2025-2030)
4.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Type (2019-2030)
4.3 Global Pancreatic Endocrine Tumor Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2019-2030)
5.1.1 Global Pancreatic Endocrine Tumor Drug Sales by Application (2019-2024)
5.1.2 Global Pancreatic Endocrine Tumor Drug Sales by Application (2025-2030)
5.1.3 Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application (2019-2030)
5.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2019-2030)
5.2.1 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2019-2024)
5.2.2 Global Pancreatic Endocrine Tumor Drug Revenue by Application (2025-2030)
5.2.3 Global Pancreatic Endocrine Tumor Drug Revenue Market Share by Application (2019-2030)
5.3 Global Pancreatic Endocrine Tumor Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Ipsen S.A.
6.1.1 Ipsen S.A. Corporation Information
6.1.2 Ipsen S.A. Description and Business Overview
6.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Product Portfolio
6.1.5 Ipsen S.A. Recent Developments/Updates
6.2 Jiangsu Hengrui Medicine Co., Ltd.
6.2.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
6.2.2 Jiangsu Hengrui Medicine Co., Ltd. Description and Business Overview
6.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product Portfolio
6.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments/Updates
6.3 MediaPharma s.r.l.
6.3.1 MediaPharma s.r.l. Corporation Information
6.3.2 MediaPharma s.r.l. Description and Business Overview
6.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product Portfolio
6.3.5 MediaPharma s.r.l. Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 OXiGENE, Inc.
6.5.1 OXiGENE, Inc. Corporation Information
6.5.2 OXiGENE, Inc. Description and Business Overview
6.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product Portfolio
6.5.5 OXiGENE, Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pancreatic Endocrine Tumor Drug Industry Chain Analysis
7.2 Pancreatic Endocrine Tumor Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pancreatic Endocrine Tumor Drug Production Mode & Process
7.4 Pancreatic Endocrine Tumor Drug Sales and Marketing
7.4.1 Pancreatic Endocrine Tumor Drug Sales Channels
7.4.2 Pancreatic Endocrine Tumor Drug Distributors
7.5 Pancreatic Endocrine Tumor Drug Customers
8 Pancreatic Endocrine Tumor Drug Market Dynamics
8.1 Pancreatic Endocrine Tumor Drug Industry Trends
8.2 Pancreatic Endocrine Tumor Drug Market Drivers
8.3 Pancreatic Endocrine Tumor Drug Market Challenges
8.4 Pancreatic Endocrine Tumor Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
